![](/images/graphics-bg.png)
The Florida Melanoma Trial I : A Prospective Multicenter Phase III Trial of Postoperative Hypofractionated Adjuvant Radiotherapy with Concurrent Interferon-Alfa-2b in the Treatment of Advanced Stage III Melanoma with Long-Term Toxicity Follow-Up
المؤلفون المشاركون
DeConti, Ronald
Rao, Nikhil
Finkelstein, Steven Eric
Yu, Daohai
Feun, Lynn
Sondak, Vernon K.
Trotti, Andy
Zhu, Weiwei
Reintgen, Douglas
Cruse, Wayne
Gwede, Clement
المصدر
العدد
المجلد 2012، العدد 2012 (31 ديسمبر/كانون الأول 2012)، ص ص. 1-10، 10ص.
الناشر
Hindawi Publishing Corporation
تاريخ النشر
2012-02-19
دولة النشر
مصر
عدد الصفحات
10
التخصصات الرئيسية
الملخص EN
Radiotherapy (RT) and interferon-alfa-2b (IFN α-2b) have individually been used for adjuvant therapy stage III melanoma with high-risk pathologic features.
We hypothesized that concurrent adjuvant RT and IFN α-2b may decrease the risk of regional recurrence following surgery with acceptable toxicity.
A prospective multicenter phase I/II study was conducted to evaluate hypofractionated RT with concurrent IFN.
Induction IFN α-2b, 20 MU/m2/d, was administered IV ×5 consecutive days every week for 4 weeks.
Next, RT 30 Gy in 5 fractions was given with concurrent IFN α-2b, 10 MU/m2 SQ 3 times per week on days alternating with RT.
Subsequent maintenance therapy consisted of adjuvant IFN α-2b, 10 MU/m2 SQ 3 times per week to a total of 1 year.
To fully evaluate patterns of failure, long-term follow-up was conducted for up to 10 years.
A total of 29 consenting patients were enrolled between August 1997 and March 2000.
The maximum (worst) grade of acute nonhematologic toxicity during concurrent RT/IFN α-2b (and up to 2 weeks post RT) was grade 3 skin toxicity noted in 2 patients (9%).
Late effects were limited.
Probability of regional control was 78% (95% CI: 55%–90%) at 12 months.
The median follow-up (range) was 80 (51–106) months among ten survivors (43%).
The median overall survival was 34.5 months while the median failure-free survival was 19.9 months.
Postoperative concurrent hypofractionated RT with IFN α-2b for advanced stage III melanoma appears to be associated with acceptable toxicity and may provide reasonable in-field control in patients at high risk of regional failure.
نمط استشهاد جمعية علماء النفس الأمريكية (APA)
Finkelstein, Steven Eric& Trotti, Andy& Rao, Nikhil& Reintgen, Douglas& Cruse, Wayne& Feun, Lynn…[et al.]. 2012. The Florida Melanoma Trial I : A Prospective Multicenter Phase III Trial of Postoperative Hypofractionated Adjuvant Radiotherapy with Concurrent Interferon-Alfa-2b in the Treatment of Advanced Stage III Melanoma with Long-Term Toxicity Follow-Up. ISRN Immunology،Vol. 2012, no. 2012, pp.1-10.
https://search.emarefa.net/detail/BIM-463512
نمط استشهاد الجمعية الأمريكية للغات الحديثة (MLA)
Finkelstein, Steven Eric…[et al.]. The Florida Melanoma Trial I : A Prospective Multicenter Phase III Trial of Postoperative Hypofractionated Adjuvant Radiotherapy with Concurrent Interferon-Alfa-2b in the Treatment of Advanced Stage III Melanoma with Long-Term Toxicity Follow-Up. ISRN Immunology No. 2012 (2012), pp.1-10.
https://search.emarefa.net/detail/BIM-463512
نمط استشهاد الجمعية الطبية الأمريكية (AMA)
Finkelstein, Steven Eric& Trotti, Andy& Rao, Nikhil& Reintgen, Douglas& Cruse, Wayne& Feun, Lynn…[et al.]. The Florida Melanoma Trial I : A Prospective Multicenter Phase III Trial of Postoperative Hypofractionated Adjuvant Radiotherapy with Concurrent Interferon-Alfa-2b in the Treatment of Advanced Stage III Melanoma with Long-Term Toxicity Follow-Up. ISRN Immunology. 2012. Vol. 2012, no. 2012, pp.1-10.
https://search.emarefa.net/detail/BIM-463512
نوع البيانات
مقالات
لغة النص
الإنجليزية
الملاحظات
Includes bibliographical references
رقم السجل
BIM-463512
قاعدة معامل التأثير والاستشهادات المرجعية العربي "ارسيف Arcif"
أضخم قاعدة بيانات عربية للاستشهادات المرجعية للمجلات العلمية المحكمة الصادرة في العالم العربي
![](/images/ebook-kashef.png)
تقوم هذه الخدمة بالتحقق من التشابه أو الانتحال في الأبحاث والمقالات العلمية والأطروحات الجامعية والكتب والأبحاث باللغة العربية، وتحديد درجة التشابه أو أصالة الأعمال البحثية وحماية ملكيتها الفكرية. تعرف اكثر
![](/images/kashef-image.png)